Engflag

Solutina

Quick links to important sections

Solutina

Solutina_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solutina

Property Description
Active Ingredients Naphazoline and Pheniramine
Form Aqueous Solution (Ophthalmic/Nasal)
Pharmacological Class Sympathomimetic/Antihistamine Combination
General Purpose Symptomatic relief of localized irritation and congestion
Origin Synthetic

What Type of Medicine is Solutina?

Solutina is a synthetic, fixed-dose combination pharmaceutical preparation for topical administration, categorized as a dual-action agent that pairs a sympathomimetic decongestant with an Histamine H1 receptor antagonist. This drug falls into the class of over-the-counter (OTC) ophthalmic or nasal preparations, clinically recognized for the temporary symptomatic relief of common seasonal irritations. Its identity rests on its intentional combination therapy, which differentiates it from single-entity decongestant products by offering comprehensive relief for allergic symptoms. The drug is exclusively intended for local use, limiting systemic exposure.

Composition and Dual-Action Purpose

The formulation’s core lies in its two active ingredients: Naphazoline (a potent alpha1-adrenergic agonist) and Pheniramine (a first-generation antihistamine). Naphazoline, an imidazoline derivative, provides rapid congestion relief, while Pheniramine, an alkylamine derivative, counteracts the chemical triggers of allergies. This specific dual mechanism is supported by pharmacological studies that confirm its ability to effectively target both the vascular symptoms of swelling and the mast cell-mediated allergic response. The product is manufactured as a sterile, aqueous solution, confirming its suitability for delicate surface application and its fast-acting effect.

Regulatory References

  1. DailyMed, NIH
  2. MedlinePlus, NIH

What side effects are possible with Solutina?

Possible Side Effects and Safety Information

The safety profile of Solutina, whose active ingredient is Solifenacin, is primarily defined by anticholinergic adverse reactions which frequently affect multiple body systems. Regulatory documents classify dry mouth as a very common adverse reaction. Constipation, blurred vision, and urinary tract infection are listed as common effects reported in clinical trials, predominantly impacting the Gastrointestinal, Eye, and Renal systems.

Serious and Clinically Significant Adverse Reactions

Official prescribing information documents rare but potentially life-threatening reactions such as angioedema (swelling of the face, tongue, and/or larynx) and anaphylactic reactions. Use is strictly contraindicated in patients with pre-existing conditions that pose safety risks, including urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma. Furthermore, the antimuscarinic action may inhibit perspiration, increasing the risk of heat stroke.

Safety Considerations for Specific Populations

Safety notes address conditions that increase systemic exposure to the active substance. Use is not recommended in individuals with severe hepatic impairment (Child-Pugh C). For patients with severe renal impairment or moderate hepatic impairment, the regulatory documents require a lower maximum daily dose. Central nervous system (CNS) anticholinergic effects, such as confusion or hallucinations, should be monitored for, as they may occur particularly after beginning treatment or increasing the dose.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation confirms that Solutina overdosage is characterized by severe antimuscarinic effects, which define the primary clinical risk and management approach. The core manifestations primarily involve the Central Nervous System (CNS) and the cardiovascular system, which is why close monitoring is required.

Documented clinical findings include a decreased level of consciousness, mental status changes such as confusion or hallucinations, and specific signs like fixed and dilated pupils and tremors. Cardiovascular findings, including fast heartbeat (tachycardia), are also listed in the regulatory profile.

These critical signs trigger mandatory emergency actions. Individuals must contact a poison control helpline or hospital immediately. Immediate emergency services (e.g., 911) must be called if the person has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened, as these are defined as life-threatening scenarios requiring urgent medical intervention.

Management is strictly symptomatic and supportive, as the official labeling states no specific antidote is known. Documented procedural steps include general supportive measures, mandatory ECG monitoring to evaluate cardiac status, and procedures such as gastric lavage which are referenced in the official summaries for overdosage treatment.

Therapeutic Uses of Solutina

What Solutina Treats: Main Uses and Benefits

Solutina is primarily used to provide symptomatic relief for adults experiencing Overactive Bladder (OAB). The medication helps address symptoms that create noticeable physiological strain related to this condition. Solifenacin (the active ingredient in Solutina) is used to manage OAB, which causes sudden urges to urinate that may be hard to control.

Easing Sudden and Frequent Urges

Solutina is commonly used to help with a cluster of symptoms, including urinary urgency, urinary frequency, and urge incontinence (involuntary leakage). It is applied in situations involving certain distressing symptoms that can interfere with daily functioning. This use contributes to improved day-to-day comfort during symptomatic periods, providing support that helps ease the overall symptom burden.

“Solutina supports the patient during difficult episodes by easing distress.”

Improving Bladder Control and Daily Comfort

This therapy is relevant for easing the disruptive manifestations of urge incontinence. By addressing this symptom, Solutina provides supportive relief when symptoms interfere with routine activities, supports general well-being during symptomatic phases. Ultimately, this supports the patient during difficult episodes and contributes to easing the overall symptom load.

Quick Fact: Relief for Urinary Urgency

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Solutina?

Eligibility to use Solutina (Naphazoline/Pheniramine Ophthalmic Solution) is defined by official regulatory criteria, focusing on age, pre-existing health conditions, and hypersensitivity status.

Approved Populations:

Solutina is officially established for use in adults and children aged 6 years and older. Use in children younger than 6 is not established, and parents must consult a healthcare professional before administration. Use in infants and very young children is strictly not recommended due to the risk of severe effects if accidentally ingested.

Absolute Contraindications:

Solutina must not be used by individuals who have a known hypersensitivity or allergy to Naphazoline, Pheniramine, or any other component in the formulation.

Conditional Use (Consult a Doctor):

Official labeling mandates that a doctor must be consulted prior to use if the patient has any of the following pre-existing conditions:

  • Narrow-angle glaucoma
  • Heart disease or high blood pressure (hypertension)
  • Overactive thyroid (hyperthyroidism)
  • Trouble urinating (e.g., due to an enlarged prostate)

Pregnancy and Lactation:

Use during pregnancy or while breastfeeding is restricted and requires a doctor's advice, as the safety profile for these populations is not fully established.

What should I know about interactions with other medicines?

Solutina Interactions with other medicines and products

The most significant concern regarding co-administration of Solutina is the potential for enhanced Central Nervous System (CNS) depression. Solutina, which acts as a GABA B receptor agonist, carries a substantial risk of additive sedative effects when combined with other agents that slow brain activity.

Clinically Significant Interactions

Product Class Examples of Interacting Medicines Interaction Mechanism & Risk
CNS Depressants Opioids (e.g., morphine, oxycodone), Benzodiazepines (e.g., alprazolam, diazepam), Sedative Hypnotics, Alcohol Additive CNS depression, leading to severe drowsiness, respiratory depression, profound sedation, and potentially coma. This combination requires extreme caution or avoidance.
Skeletal Muscle Relaxants Tizanidine, cyclobenzaprine Increased muscular relaxation and sedation, compounding the risk of motor impairment and respiratory difficulty.

Other Potential Interactions

Solutina is primarily metabolized by the Cytochrome P450 (CYP) enzyme system, particularly the CYP3A4 pathway. Co-administration with strong inhibitors or inducers of this enzyme can alter Solutina's blood concentrations. CYP3A4 inhibitors (such as certain antifungal or anti-HIV medications) may increase Solutina levels, raising the risk of dose-related adverse effects like excessive sedation. Conversely, CYP3A4 inducers (such as rifampin or phenytoin) may decrease Solutina levels, potentially reducing its therapeutic effect. These pharmacokinetic interactions necessitate dose monitoring and potential adjustment to maintain safety and effectiveness.

Mechanism of Action

Solutina functions as a mast cell stabilizer, acting at the surface of mast cells primarily within targeted mucosal tissues, such as those lining the airways and conjunctiva. The drug prevents the degranulation of the mast cell, which is the process of releasing preformed and newly synthesized inflammatory mediators. This stabilizing action involves the modulation of a sustained intracellular calcium ion influx that is typically induced by antigen binding to IgE antibodies on the mast cell surface.

By attenuating this transmembrane calcium current, Solutina inhibits the activation cascade necessary for vesicle fusion and exocytosis. Downstream consequences include the prevention of the release of key mediators, specifically histamine and leukotrienes, from the mast cell granules into the local tissue environment. This mechanistic blockade results in a system-level attenuation of localized inflammation, characterized by reduced vasodilation and decreased microvascular permeability.

Dosage and Administration Information

How to Use Solutina Ophthalmic Solution: Official Administration Guidelines

Solutina is administered through the topical ophthalmic route (applied to the eye) according to a fixed schedule for adult and pediatric patients 3 years of age and older. The proper use of this medicine depends on adhering to the exact dosing frequency and administration technique.

Dosing and Scheduling

The recommended dosage is to instill one drop in the affected eye(s) twice daily (approximately 12 hours apart). If a dose is missed, apply the missed dose as soon as possible, unless it is almost time for the next dose; in that case, the missed dose should be skipped (do not double the dose). Treatment should then continue with the regular dosing schedule.

Procedural Steps and Special Conditions

Administration must follow strict procedural rules to ensure sterility and proper absorption:

  • Handwashing and Contamination: Wash hands thoroughly before use. To prevent contamination or eye injury, do not touch the vial tip to the eye or any other surface.
  • Contact Lenses: Remove contact lenses prior to administration. Lenses may be reinserted 15 minutes following administration.
  • Co-administration: If using other topical ophthalmic drugs, they must be administered at least 5 minutes apart from Solutina.
  • Packaging: The solution is supplied in single-dose vials. Each vial must be used immediately after opening for dosing both eyes, and the vial, along with any remaining contents, must be discarded immediately after use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solutina

Evidence for Use in Overactive Bladder Symptoms

The primary research for Solutina has been conducted in adults who experience symptoms of Overactive Bladder (OAB). This research base includes several short-term, double-blind Randomized Controlled Trials (RCTs), where patients were observed over defined time intervals. These studies were used in research exploring how symptoms change over time and involved a large number of patients to provide context for the core evidence.

Research examined how patient-reported symptoms, such as the number of daily urgency episodes, micturition frequency, and incontinence episodes, were the focus of measurement. These outcomes are related to physical discomfort and describing outcomes related to daily functioning. The findings describe patterns observed in these study populations, contributing to the broader evidence landscape for conditions characterized by fluctuating or episodic manifestations.

Primary Outcomes Measured in Clinical Trials

The clinical trials applied in studies examining patient-reported experiences focused on specific outcomes. These included detailed functional measures recorded via patient diaries, such as the volume voided per micturition. Additionally, studies monitored changes in patient-reported outcomes (PROs) describing perceived discomfort, symptom intensity, and overall quality of life. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience during episodes of heightened symptom activity.

Comparative Research and Placebo Performance

This section will describe the evidence regarding Solutina's comparison against a placebo (an inactive agent) and against other compounds for managing Overactive Bladder symptoms.

A significant portion of the evidence describes patterns related to how Solutina was evaluated against an inactive treatment, known as a placebo. Research explored how outcomes were observed when Solutina was compared against an inactive agent (placebo). Furthermore, advanced research synthesis, such as network meta-analyses, was also studied in research comparing it with other similar compounds. This allows findings to provide context on the evidence landscape relative to other compounds.

Long-Term Studies and Follow-up Duration

This part of the overview will summarize the available data on treatment duration, explaining what is known about outcomes beyond the initial 12-week trials and the duration of observation periods in the existing research.

Evidence in Special Populations

This section will outline what research exists for distinct patient groups, focusing on the studies that have examined Solutina in older adults and the separate body of evidence available for pediatric patients with Neurogenic Detrusor Overactivity.

What Remains Uncertain About the Research

Research provides context but not individual predictions. The certainty of the evidence regarding outcomes beyond one year remains low, as data for long-term outcomes past the approximately 52-week mark remain insufficient. While extensive research has been conducted, comparative evidence is continually being updated, and some scientific reviews suggest the need for newer data synthesis to incorporate the most recent trial findings.

Frequently Asked Questions (FAQ)

Common questions about Solutina (FAQ)

Q: Can I take Solutina if I am pregnant or planning to be?

Official documents state that the safety of using this product during pregnancy is not fully established. Information indicates that discussion with a healthcare professional is needed before using the medication if one is pregnant or planning to conceive. This process is necessary to fully review the available official information.

Q: Is Solutina safe to use while breastfeeding?

Official documentation indicates that it is currently unknown whether the active ingredients of Solutina pass into breast milk or if they could affect a nursing child. Because of this uncertainty, official sources advise discussing product use with a doctor before making a decision while breastfeeding.

Q: Is there a certain food or drink I should avoid while on Solutina?

Regulatory documents describe that alcohol may contribute to an increased risk of drowsiness and sedation when combined with Solutina. Outside of this warning regarding alcohol, the product labeling does not commonly list specific non-alcoholic foods or drinks.

Q: How long does it usually take before I can expect Solutina to start working?

Official information indicates that the Naphazoline component of the product is described as a rapid-acting vasoconstrictor. Studies have been designed to measure the medication’s initial effect on relieving redness starting at time points as early as 10 minutes following administration.

Q: How does the body typically eliminate Solutina?

Official information indicates that the drug is primarily processed, or metabolized, by the body’s Cytochrome P450 (CYP) enzyme system. Specifically, the CYP3A4 pathway is described as playing a major role in breaking down the active substance.

Q: Are there any long-term health risks associated with taking Solutina for years?

Official product labeling advises that use of this product is typically for a short duration, noting that it is not intended for use longer than 72 hours unless a doctor has provided specific guidance. Research evidence regarding outcomes for use extending beyond approximately one year (52 weeks) remains limited.

Q: Does Solutina come in a generic version?

Regulatory records confirm that generic options for this fixed-dose combination are available. The FDA has approved Abbreviated New Drug Applications (ANDAs), which allow for the marketing of generic versions of the Naphazoline/Pheniramine Ophthalmic Solution.

Q: Is it normal to feel tired when first starting Solutina?

Drowsiness, or sedation, is a known possible effect associated with one of the active ingredients, the antihistamine Pheniramine. This effect is sometimes reported in connection with the use of the medication.

Q: Can I use Solutina if I have kidney problems?

Regulatory documents indicate that official guidance exists for the use of this product in patients with severe renal impairment. For any kidney condition, reviewing the official prescribing criteria with a doctor is necessary to determine appropriateness of use.

Q: Does Solutina lose its effectiveness over time?

Official warnings describe that frequent or prolonged use of the product may be associated with an increase in eye redness. This is known as a rebound effect, which is related to the medication's effectiveness diminishing with continued use.

Q: What should I do if I think I'm having a serious reaction to Solutina?

Official product information describes specific instances when use should be discontinued and medical help sought, such as if symptoms like eye pain, vision changes, or worsening irritation persist for more than three days. It is strongly warned that in case of accidental oral ingestion, immediate professional assistance or contact with a Poison Control Center is necessary.

Q: What is the difference between Solutina and the compound it’s made from?

Solutina is a synthetic, fixed-dose combination product that incorporates two different active compounds, Naphazoline and Pheniramine, in one solution. This combination is designed to provide dual-action relief: Naphazoline acts as a decongestant, and Pheniramine acts as an antihistamine, addressing both eye redness and itching.

Q: Can Solutina affect my ability to drive or operate machinery?

Regulatory warnings describe that this medication may cause temporary blurred vision, which could affect activities requiring clear sight. The official advice is to wait until vision has cleared before attempting to drive or operate machinery.

Q: Are there different strengths of Solutina available?

Regulatory information indicates that the Naphazoline/Pheniramine combination is available in different strengths. These variations are noted in official sources for the purpose of distinguishing different product presentations.

Q: Does Solutina have a 'Black Box Warning' in the US?

The official product labeling for this specific ophthalmic solution does not contain a formal Black Box Warning. However, the label does include a prominent safety warning concerning the risk of severe complications or coma following accidental oral ingestion by infants and young children.

Q: What is the shelf life or expiry of Solutina?

Official labeling states that the product must be stored at a controlled room temperature and used before the expiration date marked on the packaging. Instructions further advise that any remaining product in a single-use vial is intended to be discarded immediately after application.

Q: Is Solutina considered a high-risk medication by regulatory bodies?

Regulatory documents classify the drug as an Over-the-Counter (OTC) product, meaning it is generally available without a prescription. Despite this classification, the labeling includes strong warnings regarding the risks associated with accidental ingestion by children and lists specific adverse reactions that require medical consultation.

Q: Does Solutina affect sleep patterns?

The medication contains an antihistamine component that is associated with sedative effects, which includes drowsiness. The potential for drowsiness, combined with the risk of temporary blurred vision, suggests that the use of this product may influence sleep.

How should Solutina be stored and disposed of?

How to Store and Dispose of Solutina?

Official regulatory guidelines strictly define the conditions necessary to store and dispose of Solutina (Naphazoline/Pheniramine Ophthalmic Solution) to ensure its stability and safety.

Storage Requirements

Solutina must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from freezing and excessive heat, as these conditions can compromise the solution. The container should be kept tightly closed when not in use and stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Solutina should not be poured down a drain or flushed down a toilet. To properly discard the medicine, follow official instructions by utilizing a drug take-back program or by mixing the product with an undesirable substance and sealing it before placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Solutina found in:

A-Z Index: